NEW YORK (GenomeWeb News) – Exagen Diagnostics, which develops genomic tests aimed at rheumatology, announced on Monday the completion of a financing round that raised $5.3 million.

The funding will be used to expand the market for the Albuquerque, NM-based firm's brands and further development of near-term pipeline products, it said. Exagen plans to expand its three marketed rheumatology brands — Avise SLE, Avise PG, and Avise MCV — and other products that will help physicians diagnose and treat rheumatologic disorders, company President and CEO Ron Rocca said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.